These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 14705860)

  • 1. Early drug safety evaluation: biomarkers, signatures, and fingerprints.
    Roberts R; Cain K; Coyle B; Freathy C; Leonard JF; Gautier JC
    Drug Metab Rev; 2003 Nov; 35(4):269-75. PubMed ID: 14705860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zebrafish based assays for the assessment of cardiac, visual and gut function--potential safety screens for early drug discovery.
    Berghmans S; Butler P; Goldsmith P; Waldron G; Gardner I; Golder Z; Richards FM; Kimber G; Roach A; Alderton W; Fleming A
    J Pharmacol Toxicol Methods; 2008; 58(1):59-68. PubMed ID: 18585469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
    Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
    J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine Learning Uses Chemo-Transcriptomic Profiles to Stratify Antimalarial Compounds With Similar Mode of Action.
    van Heerden A; van Wyk R; Birkholtz LM
    Front Cell Infect Microbiol; 2021; 11():688256. PubMed ID: 34268139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.
    Bhushan A; Martucci NJ; Usta OB; Yarmush ML
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):475-7. PubMed ID: 26940609
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of a pharmaceutical database as an aid to the nonclinical detection of drug-induced cardiac toxicity.
    De Alwis D; Foley CM; Herman E; Hill AP; Hoffmann PK; Kanda Y; Kaushik E; Pierson J; Puglisi R; Shi H; Yang X; Pugsley MK
    J Pharmacol Toxicol Methods; 2024; 127():107507. PubMed ID: 38636673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging technologies and challenges for better and safer drugs.
    Theodosiou M; Amir-Aslani A; Mégarbane B
    Biotechnol Lett; 2014 Apr; 36(4):677-84. PubMed ID: 24243233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
    Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
    Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationalizing Secondary Pharmacology Screening Using Human Genetic and Pharmacological Evidence.
    Deaton AM; Fan F; Zhang W; Nguyen PA; Ward LD; Nioi P
    Toxicol Sci; 2019 Feb; 167(2):593-603. PubMed ID: 30346593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs in control samples in nonclinical safety studies: a reconsideration.
    Zimmer D
    Bioanalysis; 2016 May; 8(10):1003-7. PubMed ID: 27080047
    [No Abstract]   [Full Text] [Related]  

  • 13. A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity.
    Kuepfer L; Clayton O; Thiel C; Cordes H; Nudischer R; Blank LM; Baier V; Heymans S; Caiment F; Roth A; Fluri DA; Kelm JM; Castell J; Selevsek N; Schlapbach R; Keun H; Hynes J; Sarkans U; Gmuender H; Herwig R; Niederer S; Schuchhardt J; Segall M; Kleinjans J
    Arch Toxicol; 2018 Jan; 92(1):553-555. PubMed ID: 28852801
    [No Abstract]   [Full Text] [Related]  

  • 14. Methodological innovations expand the safety pharmacology horizon.
    Pugsley MK; Curtis MJ
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
    Colburn WA; Lee JW
    Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of proteomic technologies in the drug development process.
    Walgren JL; Thompson DC
    Toxicol Lett; 2004 Apr; 149(1-3):377-85. PubMed ID: 15093284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of transgenic animals in understanding molecular mechanisms of toxicity.
    Wolf CR; Henderson CJ
    J Pharm Pharmacol; 1998 Jun; 50(6):567-74. PubMed ID: 9680065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of histologically defined specific biomarkers in drug development with special reference to the glutathione S-transferases.
    Shaw M
    Cancer Biomark; 2005; 1(1):69-74. PubMed ID: 17192033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A predictive index of biomarkers for ictogenesis from tier I safety pharmacology testing that may warrant tier II EEG studies.
    Gauvin DV; Zimmermann ZJ; Yoder J; Harter M; Holdsworth D; Kilgus Q; May J; Dalton J; Baird TJ
    J Pharmacol Toxicol Methods; 2018; 94(Pt 1):50-63. PubMed ID: 29751085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes.
    Holmgren G; Sjögren AK; Barragan I; Sabirsh A; Sartipy P; Synnergren J; Björquist P; Ingelman-Sundberg M; Andersson TB; Edsbagge J
    Drug Metab Dispos; 2014 Sep; 42(9):1401-6. PubMed ID: 24980256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.